Alumis’ (ALMS) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Alumis (NASDAQ:ALMS) in a research report released on Friday morning,Benzinga reports. They currently have a $26.00 target price on the stock.

Several other brokerages also recently weighed in on ALMS. Baird R W raised shares of Alumis to a “strong-buy” rating in a research note on Thursday, October 31st. Cantor Fitzgerald reiterated an “overweight” rating on shares of Alumis in a report on Thursday, November 14th. Finally, Robert W. Baird initiated coverage on shares of Alumis in a research note on Thursday, October 31st. They set an “outperform” rating and a $25.00 price objective on the stock. Six analysts have rated the stock with a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Buy” and a consensus target price of $26.83.

Alumis Stock Up 2.2 %

Alumis stock opened at $8.82 on Friday. Alumis has a fifty-two week low of $7.66 and a fifty-two week high of $13.53. The business’s fifty day moving average is $10.21.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of ALMS. Barclays PLC purchased a new stake in Alumis in the third quarter valued at approximately $197,000. Geode Capital Management LLC purchased a new stake in shares of Alumis during the 3rd quarter valued at $3,266,000. State Street Corp acquired a new stake in shares of Alumis during the 3rd quarter worth $866,000. Stifel Financial Corp purchased a new position in shares of Alumis in the 3rd quarter worth $931,000. Finally, Samsara BioCapital LLC acquired a new position in Alumis in the third quarter valued at $34,886,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.